Dynasty Market Report — October 21, 2026

The Lede

The Jalen Hurts situation is no longer a fantasy storyline — it's a front-office crisis with real dynasty consequences. The NFLPA calling for a full investigation into how Hurts' blood clots were medically managed signals this goes beyond a standard injury designation, and Hurts' DME crashing to 4,476 (down -13.39% in seven days) tells you the market is pricing in genuine long-term uncertainty. Until Philadelphia provides transparent answers, Hurts' dynasty value is uninvestable at any price that assumes a healthy 2027 and beyond.

Who's Rising

Travis Hunter's +144.19% explosion to DME 1,387 is the headline of the week — rookie breakout confirmation is hitting the market hard, and JAX clearly found something. At 1,387 he's still below his realistic ceiling if the target share holds; buy aggressively before the broader market catches up. J.J. McCarthy (DME 1,720, +66.67%) and Germie Bernard (DME 1,987, +47.19%) are moving in tandem — Minnesota's offense is clicking and PIT found a receiver worth building around, respectively — hold both and resist the urge to sell into the hype.

Who's Falling

Marvin Harrison Jr. falling to DME 2,293 (-22.72%) is jarring for a player with his pedigree, but ARI's offensive dysfunction is a real ceiling-suppressor right now — this is a buy-low window, not a panic sell. Rashee Rice at DME 2,700 (-15.68%) is more concerning in context: with Cyrus Allen (DME 1,097, +24.8%) rising fast in KC, Rice's target share story is getting complicated, and that's a structural issue, not a blip.

The Move

Sell Jalen Hurts now. DME 4,476 still reflects too much optimism given a blood clot investigation that implicates team medical staff. Call the Hurts manager in your league today, offer a package centered on Isaiah Likely (DME 2,803, ascending TE1 upside) plus a 2027 first, and let them hold the medical and legal uncertainty. Value is on your side.